SCHEMBL4773624

SCHEMBL4773624

Nc1cccc(-c2cc3c(Nc4cccc(Cl)c4)ncnc3[nH]2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 12/20 0.59
ERBB2 P04626 1/20 0.59
ABL1 P00519 3/20 0.58
CDK1 P06493 1/20 0.58
PRKCA P17252 1/20 0.58
TTBK1 Q5TCY1 1/20 0.57
TTBK2 Q6IQ55 1/20 0.57
ABL2 P42684 2/20 0.54
BRAF P15056 4/20 0.53
TNNI3K Q59H18 4/20 0.53
FADS1 O60427 2/20 0.53
LCK P06239 1/20 0.52
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
PRNP P04156 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8259230 0.91 BRAF (0.58) EGFRERBB2ABL1CDK1PRKCA
SCHEMBL2461054 0.90 BRAF (0.64) EGFRERBB2ABL1CDK1PRKCA
SCHEMBL4770048 0.89 EGFR (0.60) EGFRERBB2ABL1CDK1PRKCA
SCHEMBL7500834 0.88 EGFR (0.58) EGFRERBB2ABL1CDK1PRKCA
SCHEMBL27442803 0.88 BRAF (0.62) EGFRERBB2ABL1CDK1PRKCA
Bromide SCHEMBL7502970 0.87 EGFR (0.57) EGFRERBB2ABL1CDK1PRKCA
SCHEMBL8256959 0.86 EIF2AK2 (0.62) EGFRTTBK1TTBK2BRAFTNNI3K
SCHEMBL7496398 0.85 EGFR (0.53) EGFRERBB2ABL1CDK1PRKCA
SCHEMBL7497275 0.85 TTBK1 (0.52) EGFRERBB2ABL1TTBK1TTBK2
SCHEMBL2461351 0.85 EGFR (0.57) EGFRABL1CDK1PRKCATTBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0836605-B1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 2002-02-06 EP claimed
EP-0836605-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF Novartis AG (CH) 1998-04-22 EP claimed
WO-1997002266-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 1997-01-23 WO claimed
EP-0938486-B1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 2008-01-16 EP disclosed
EP-0836605-B1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 2002-02-06 EP disclosed
US-6180636-B1 USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS NOVARTIS AG (CH) 2001-01-30 US disclosed
US-6140332-A Pyrrolopyrimidines and processes for the preparation thereof NOVARTIS AG (CH) 2000-10-31 US disclosed
EP-0938486-A1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION Novartis AG (CH) 1999-09-01 EP disclosed
EP-0836605-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF Novartis AG (CH) 1998-04-22 EP disclosed
WO-1998007726-A1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 1998-02-26 WO disclosed
WO-1997002266-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 1997-01-23 WO disclosed